http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1202719-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b309c1b3e320bed01df567f8063ca76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
| filingDate | 2000-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16ec5489aace8f97a43e33131a5e5712 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aacc38b0fe94ec153ebcc90c6d501a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4210cfad8abc2dcda49448b47baf805f |
| publicationDate | 2006-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1202719-B1 |
| titleOfInvention | Anesthetic composition for intravenous injection comprising propofol |
| abstract | An anesthetic composition for intravenous injection, comprising propofol (2,6-diisopropylphenol) and Poloxamer POLOXAMER (Polyoxyethylene-polyoxypropylene copolymer) as surfactant is disclosed. The composition optionally can contain at least one co-surfactant selected from the group consisting of SOLUTOL HS 15 (Macrogol-15 Hydroxystearate), egg lecithin, LABRASOL (Polyoxy capryllic glyceride), polyoxy 10-oleyl-ether, TWEEN (polyoxyethylene sorbitan fatty acid esters), ethanol and polyethylene glycol. Because the composition is usually prepared in the form of an oil-in-water microemulsion having a particle size of 100 nm and below, it has superior technical effects in that it is thermodynamically stable and can be aseptically filtered to prevent microorganism contamination. Moreover, the composition is readily prepared so that side effects such as embolism, hyperlipidemia, etc. can be minimized. |
| priorityDate | 1999-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.